171 related articles for article (PubMed ID: 25823738)
1. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.
Kelly JL; Salles G; Goldman B; Fisher RI; Brice P; Press O; Casasnovas O; Maloney DG; Soubeyran P; Rimsza L; Haioun C; Xerri L; LeBlanc M; Tilly H; Friedberg JW
J Clin Oncol; 2015 May; 33(13):1482-90. PubMed ID: 25823738
[TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.
Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI
Clin Cancer Res; 2013 Dec; 19(23):6624-32. PubMed ID: 24130072
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741.
Ng K; Sargent DJ; Goldberg RM; Meyerhardt JA; Green EM; Pitot HC; Hollis BW; Pollak MN; Fuchs CS
J Clin Oncol; 2011 Apr; 29(12):1599-606. PubMed ID: 21422438
[TBL] [Abstract][Full Text] [Related]
4. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.
Nastoupil LJ; Sinha R; Byrtek M; Zhou X; Taylor MD; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
Cancer; 2014 Jun; 120(12):1830-7. PubMed ID: 24668580
[TBL] [Abstract][Full Text] [Related]
5. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Levy R; Ganjoo KN; Leonard JP; Vose JM; Flinn IW; Ambinder RF; Connors JM; Berinstein NL; Belch AR; Bartlett NL; Nichols C; Emmanouilides CE; Timmerman JM; Gregory SA; Link BK; Inwards DJ; Freedman AS; Matous JV; Robertson MJ; Kunkel LA; Ingolia DE; Gentles AJ; Liu CL; Tibshirani R; Alizadeh AA; Denney DW
J Clin Oncol; 2014 Jun; 32(17):1797-803. PubMed ID: 24799467
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.
Chen CS; Zirpoli G; Barlow WE; Budd GT; McKiver B; Pusztai L; Hortobagyi GN; Albain KS; Damaj MI; Godwin AK; Thompson A; Henry NL; Ambrosone CB; Stringer KA; Hertz DL
J Natl Compr Canc Netw; 2023 Nov; 21(11):1172-1180.e3. PubMed ID: 37935109
[TBL] [Abstract][Full Text] [Related]
7. Immune infiltrate diversity confers a good prognosis in follicular lymphoma.
Tsakiroglou AM; Astley S; Dave M; Fergie M; Harkness E; Rosenberg A; Sperrin M; West C; Byers R; Linton K
Cancer Immunol Immunother; 2021 Dec; 70(12):3573-3585. PubMed ID: 33929583
[TBL] [Abstract][Full Text] [Related]
8. Digital and manual interfollicular Ki-67 are associated with a progression-free survival in patients with low-grade follicular lymphoma.
Nasir A; Hegerova L; Yousaf H; Forster CL; Shanley R; Linden MA; Bachanova V; Yohe S
Am J Clin Pathol; 2024 Apr; 161(4):380-387. PubMed ID: 38044670
[TBL] [Abstract][Full Text] [Related]
9. Follicular lymphoma polygenic risk score is associated with increased disease risk but improved overall survival among women in a population based case-control in Los Angeles County California.
Zhong C; Chao CR; Song JY; Weisenburger DD; Luo J; Ding YC; Neuhausen SL; Bernstein L; Cozen W; Wang SS
Cancer Epidemiol; 2020 Apr; 65():101688. PubMed ID: 32092486
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.
Cerhan JR; Wang S; Maurer MJ; Ansell SM; Geyer SM; Cozen W; Morton LM; Davis S; Severson RK; Rothman N; Lynch CF; Wacholder S; Chanock SJ; Habermann TM; Hartge P
Blood; 2007 Jun; 109(12):5439-46. PubMed ID: 17327408
[TBL] [Abstract][Full Text] [Related]
11. Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).
Wang QL; Ma C; Yuan C; Shi Q; Wolpin BM; Zhang Y; Fuchs CS; Meyer J; Zemla T; Cheng E; Kumthekar P; Guthrie KA; Couture F; Kuebler P; Kumar P; Tan B; Krishnamurthi S; Goldberg RM; Venook A; Blanke C; Shields AF; O'Reilly EM; Meyerhardt JA; Ng K
Clin Cancer Res; 2023 Jul; 29(14):2621-2630. PubMed ID: 37289007
[TBL] [Abstract][Full Text] [Related]
12. Novel agents in follicular lymphoma: choosing the best target.
Sehn LH
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):284-292. PubMed ID: 27913493
[TBL] [Abstract][Full Text] [Related]
13. Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018.
Dinnessen MAW; Visser O; Tonino SH; Posthuma EFM; Blijlevens NMA; Kersten MJ; Lugtenburg PJ; Dinmohamed AG
Blood Cancer J; 2021 Nov; 11(11):179. PubMed ID: 34775466
[No Abstract] [Full Text] [Related]
14. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.
Al Tabaa Y; Casasnovas RO; Baillet C; Bachy E; Nicolas-Virelizier E; Schiano De Colella JM; Bailly C; Kanoun S; Guidez S; Gyan E; Gressin R; Morineau N; Ysebaert L; Le Gouill S; Tilly H; Houot R; Morschhauser F; Cartron G; Herbaux C
Blood Adv; 2023 Jul; 7(14):3735-3738. PubMed ID: 37067945
[No Abstract] [Full Text] [Related]
15. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Jul; 170(2):185-91. PubMed ID: 25833790
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma.
Bruns H; Büttner M; Fabri M; Mougiakakos D; Bittenbring JT; Hoffmann MH; Beier F; Pasemann S; Jitschin R; Hofmann AD; Neumann F; Daniel C; Maurberger A; Kempkes B; Amann K; Mackensen A; Gerbitz A
Sci Transl Med; 2015 Apr; 7(282):282ra47. PubMed ID: 25855493
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
Song MK; Chung JS; Lee JJ; Lee JH; Song IC; Lee SM; Shin DY; Lee GW; Lee IS
Acta Haematol; 2015; 134(1):7-16. PubMed ID: 25832367
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Schey S; Brown SR; Tillotson AL; Yong K; Williams C; Davies F; Morgan G; Cavenagh J; Cook G; Cook M; Orti G; Morris C; Sherratt D; Flanagan L; Gregory W; Cavet J;
Br J Haematol; 2015 Aug; 170(3):336-48. PubMed ID: 25891006
[TBL] [Abstract][Full Text] [Related]
20. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
Hillmen P; Robak T; Janssens A; Babu KG; Kloczko J; Grosicki S; Doubek M; Panagiotidis P; Kimby E; Schuh A; Pettitt AR; Boyd T; Montillo M; Gupta IV; Wright O; Dixon I; Carey JL; Chang CN; Lisby S; McKeown A; Offner F;
Lancet; 2015 May; 385(9980):1873-83. PubMed ID: 25882396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
